Under the terms of the agreement, Starpharma will receive staged payments on successful completion of technical milestones within the collaborative project. The agreement also deals with commercialization rights arising from the collaboration. The collaboration will apply Starpharma’s dendrimer technology to deliver drugs through the skin with the aim of improving the effectiveness and tolerability of certain dermal treatments.
This is the fourth agreement signed by Starpharma this year to develop commercial applications for its dendrimer technology. Starpharma also has dendrimer drug delivery programs underway in cancer and protein therapeutics.
Jackie Fairley, CEO of Starpharma, said: “We consider drug delivery applications of dendrimers to represent a highly attractive commercial opportunity and we are delighted to be working with such a strong international partner in dermatology.”